company background image
ENZN

Enzon Pharmaceuticals OTCPK:ENZN Stock Report

Last Price

US$0.29

Market Cap

US$21.9m

7D

-5.1%

1Y

-44.3%

Updated

13 May, 2022

Data

Company Financials
ENZN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ENZN Stock Overview

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products.

Enzon Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enzon Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.29
52 Week HighUS$0.76
52 Week LowUS$0.25
Beta-0.037
1 Month Change-16.19%
3 Month Change-18.43%
1 Year Change-44.33%
3 Year Change32.23%
5 Year Change27.71%
Change since IPO-91.86%

Recent News & Updates

Shareholder Returns

ENZNUS BiotechsUS Market
7D-5.1%-10.9%-10.1%
1Y-44.3%-23.7%-10.8%

Return vs Industry: ENZN underperformed the US Biotechs industry which returned -23.7% over the past year.

Return vs Market: ENZN underperformed the US Market which returned -10.8% over the past year.

Price Volatility

Is ENZN's price volatile compared to industry and market?
ENZN volatility
ENZN Average Weekly Movement12.7%
Biotechs Industry Average Movement11.7%
Market Average Movement7.7%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market2.8%

Stable Share Price: ENZN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ENZN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1981n/aRick Feinsteinhttps://www.enzon.com

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug.

Enzon Pharmaceuticals Fundamentals Summary

How do Enzon Pharmaceuticals's earnings and revenue compare to its market cap?
ENZN fundamental statistics
Market CapUS$21.89m
Earnings (TTM)-US$2.82m
Revenue (TTM)US$320.00k

68.4x

P/S Ratio

-7.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENZN income statement (TTM)
RevenueUS$320.00k
Cost of RevenueUS$0
Gross ProfitUS$320.00k
Other ExpensesUS$3.14m
Earnings-US$2.82m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.038
Gross Margin100.00%
Net Profit Margin-880.94%
Debt/Equity Ratio0.0%

How did ENZN perform over the long term?

See historical performance and comparison

Valuation

Is Enzon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


5.41x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ENZN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ENZN's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ENZN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ENZN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ENZN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ENZN is overvalued based on its PB Ratio (5.4x) compared to the US Biotechs industry average (1.3x).


Future Growth

How is Enzon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enzon Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Enzon Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-41.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ENZN is currently unprofitable.

Growing Profit Margin: ENZN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ENZN is unprofitable, and losses have increased over the past 5 years at a rate of 41.1% per year.

Accelerating Growth: Unable to compare ENZN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENZN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).


Return on Equity

High ROE: ENZN has a negative Return on Equity (-1.64%), as it is currently unprofitable.


Financial Health

How is Enzon Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ENZN's short term assets ($47.5M) exceed its short term liabilities ($410.0K).

Long Term Liabilities: ENZN has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: ENZN is debt free.

Reducing Debt: ENZN has not had any debt for past 5 years.

Debt Coverage: ENZN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ENZN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Enzon Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENZN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ENZN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENZN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENZN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ENZN has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

US$226k

CEO Compensation


CEO

Rick Feinstein (78 yo)

8.42yrs

Tenure

US$225,944

Compensation

Mr. Richard L. Feinstein, also known as Rick, CPA, has been Chief Executive Officer and Company Secretary at Enzon Pharmaceuticals Inc. since February 26, 2021. He had been Vice President of Finance at Enz...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Enzon Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Enzon Pharmaceuticals, Inc.
  • Ticker: ENZN
  • Exchange: OTCPK
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$21.893m
  • Shares outstanding: 74.21m
  • Website: https://www.enzon.com

Number of Employees


Location

  • Enzon Pharmaceuticals, Inc.
  • 20 Commerce Drive
  • Suite 135
  • Cranford
  • New Jersey
  • 7016
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/13 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.